Albemarle (NYSE: ALB) exits Ketjen control and launches $500 million debt tender

Rhea-AI Filing Summary

Albemarle Corporation has completed the sale of its 51% ownership interest in Ketjen Corporation to an affiliate of KPS Capital Partners, while retaining a 49% minority stake. Albemarle expects approximately $547 million in cash from the Ketjen sale, including $22 million of cash held by Ketjen.

Combined with the earlier sale of its 50% interest in the Eurecat joint venture to Axens SA, Albemarle’s pre-tax proceeds from the two transactions total about $670 million. The company plans to use these funds for debt reduction, including cash tender offers of up to $500 million for several series of senior notes and the full redemption of $650,000,000 of 4.650% Senior Notes due 2027.

Positive

• Strategic portfolio reshaping with cash realization: Albemarle completed the Ketjen stake sale and Eurecat joint-venture exit, generating approximately $670 million in combined pre-tax proceeds while retaining a 49% minority interest in Ketjen and full ownership of the Performance Catalyst Solutions business.
• Meaningful debt reduction initiatives: The company plans cash tender offers for up to $500 million of various senior notes and will fully redeem $650,000,000 of 4.650% Senior Notes due 2027, targeting lower leverage and interest expense.

Negative

• None.

Insights

Corporate finance and capital structure analyst

Albemarle divests Ketjen stake and moves to retire higher-cost debt.

Albemarle has monetized non-core catalyst assets, completing the Ketjen sale and the Eurecat joint-venture exit for combined pre-tax proceeds of approximately $670 million. It keeps a 49% minority stake in Ketjen and 100% of the Performance Catalyst Solutions business, tightening portfolio focus.

The company intends to deploy proceeds toward liability management: cash tender offers capped at $500 million for four series of longer-dated senior notes and a full redemption of $650,000,000 of 4.650% Senior Notes due 2027. This mix targets both near-term and long-duration debt.

If completed as described in the Offer to Purchase and redemption notice, these steps would reduce gross debt and interest obligations and could improve financial flexibility. Actual impact will depend on investor participation in the tender offers and final pricing mechanics described for settlement on the noted March 2026 dates.

false000091591300009159132026-03-022026-03-020000915913us-gaap:CommonStockMember2026-03-022026-03-020000915913us-gaap:SeriesAPreferredStockMember2026-03-022026-03-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________________

FORM 8-K

_________________________________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2026

_________________________________

ALBEMARLE CORPORATION

(Exact name of registrant as specified in charter)

_________________________________

Virginia

001-12658

54-1692118

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

4250 Congress Street, Suite 900

Charlotte, North Carolina 28209

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (980) 299-5700

Not applicable

(Former name or former address, if changed since last report.)

_________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a- 12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

COMMON STOCK, $.01 Par Value

ALB

New York Stock Exchange

DEPOSITARY SHARES, each representing a 1/20th interest in a share of 7.25% Series A Mandatory Convertible Preferred Stock

ALB PR A

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.01    Completion of Acquisition or Disposition of Assets.

On March 2, 2026, Albemarle Corporation, a Virginia corporation (the “Company” or “Albemarle”), completed the previously announced sale of its 51% ownership interests (the “Sale”) in Ketjen Corporation, a Delaware corporation (“Ketjen”), to ChemCat AcquisitionCo, LLC, a Delaware limited liability company organized by and affiliated with KPS Capital Partners LP, a New York based private equity firm. Ketjen’s business consists of developing, manufacturing (including through toll manufacturing arrangements), and marketing catalysts and related products on a global basis.

In connection with the Sale, Albemarle expects to receive an aggregate amount of approximately $547 million in cash, inclusive of $22 million in cash included with Ketjen at the time of the Sale. Together with the sale of its 50% interest in the Eurecat joint venture to Axens SA, completed in January 2026, Albemarle’s combined pre-tax proceeds for the two transactions total approximately $670 million.

At close of the Sale, Albemarle retains a 49% minority ownership interest in Ketjen. Albemarle also will retain 100% ownership of Ketjen’s Performance Catalyst Solutions business, which has been integrated into Albemarle’s product portfolio.

Item 7.01    Regulation FD Disclosure.

On March 2, 2026, the Company issued a press release regarding the sale of its ownership interests in Ketjen, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 and in Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall either be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific references in such a filing.

Item 8.01.    Other Events.

On March 2, 2026, the Company issued a press release announcing the redemption of its 4.650% Senior Notes due 2027 and its offers to purchase for cash up to an aggregate purchase price of $500 million for (i) its 5.65% Senior Notes due 2052, (ii) its 5.45% Senior Notes due 2044, (iii) the 3.45% Senior Notes due 2029 of Albemarle Wodgina Pty Ltd, a wholly-owned subsidiary of the Company, and (iv) its 5.05% Senior Notes due 2032, upon the terms and subject to the conditions set forth in an Offer to Purchase, dated March 2, 2026.

A copy of the press release is filed as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number						Exhibit
2.1						Stock Purchase Agreement, by and among Albemarle Corporation, Ketjen Corporation and ChemCat AcquisitionCo, LLC, dated as of October 25, 2025. [Filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K (No. 1-12658) filed on October 27, 2025, and incorporated herein by reference].
99.1*						Press release, dated March 2, 2026 issued by the Company.
99.2*						Press release, dated March 2, 2026 issued by the Company.
104*						Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Included with this filing.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain information contained herein and in the exhibit hereto that are not statements of historical fact or current fact constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties, often contain words such as “ambition” “anticipate,” “believe,” “estimate,” “expect,” ”goal” “guidance,” “intend,” “may,” “outlook,” and “scenario” “should,” “would,” “will” and similar references to future periods. Forward-looking statements may include statements regarding: approximate proceeds from the Sale and related transactions; the Company's plans to use proceeds from the Sale to fund the tender offers and redemption described herein; the anticipated completion of the tender offers and redemption of notes; and all other information relating to matters that are not historical facts. These and other forward-looking statements are based on management’s current estimates, assumptions and expectations and involve risks and uncertainties that could significantly affect expected results. Actual results could differ materially from those expressed or implied in the forward-looking statements if one or more of the underlying estimates, assumptions or expectations prove to be inaccurate or are unrealized. Factors that could cause Albemarle’s actual results to differ materially from the outlook expressed or implied in any forward-looking statement include: changes in inflation or interest rates; volatility in the debt and equity market; changes in credit ratings; the Company’s ability to complete the tender offers on anticipated terms or at all; changes in economic and business conditions; changes in trade policies and tariffs; completion of the audit of our annual financial statements; fluctuations in foreign currencies; changes in laws and government regulation; regulatory actions, proceedings, claims or litigation; cyber-security breaches, terrorist attacks, industrial accidents or natural disasters; geopolitical conflicts and political unrest; and the other factors detailed from time to time in the reports Albemarle files with the SEC, including those described under “Risk Factors” in Albemarle’s most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q, which are filed with the SEC and available on the investor section of Albemarle’s website (investors.albemarle.com) and on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date of this Form 8-K. Albemarle assumes no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						ALBEMARLE CORPORATION
Date: March 6, 2026						By:			/s/ Ander C. Krupa
									Ander C. Krupa
									General Counsel and Corporate Secretary

Exhibit 99.1

Press Release

Albemarle Completes Sale of Controlling Stake in Ketjen to KPS Capital Partners

CHARLOTTE, N.C., March 2, 2026 – Albemarle Corporation (NYSE: ALB), a global leader in providing essential elements for mobility, energy, connectivity, and health, today announced it has completed the sale of a controlling stake in Ketjen Corporation’s refining catalyst solutions business (Ketjen) to affiliates of KPS Capital Partners, LP (KPS).

Albemarle retains a minority stake in Ketjen, with KPS having a majority of the Board of Directors and operational control. Albemarle retains 100% ownership of Ketjen’s Performance Catalyst Solutions business, which has been integrated into Albemarle’s product portfolio.

Combined with the sale of its 50% interest in the Eurecat joint venture to Axens SA, which was completed in January 2026, Albemarle has received a combined $670 million in pre-tax proceeds between the two transactions. Albemarle expects to use the proceeds for debt reduction and other general corporate purposes.

“Our continued investment in Ketjen alongside KPS demonstrates our confidence in the company’s growth and value-creation potential,” said Kent Masters, Chairman and CEO of Albemarle. “We are committed to supporting Ketjen’s next chapter while strengthening Albemarle’s portfolio focus and financial flexibility.”

Goldman Sachs & Co. LLC acted as exclusive financial advisor, and K&L Gates LLP served as legal advisor to Albemarle for the transaction.

About Albemarle 
Albemarle Corporation (NYSE: ALB) leads the world in transforming essential resources into critical ingredients for mobility, energy, connectivity and health. We partner to pioneer new ways to move, power, connect and protect with people and planet in mind. A reliable and high-quality global supply of lithium and bromine allows us to deliver advanced solutions for our customers. Learn more about how the people of Albemarle are enabling a more resilient world at Albemarle.com.

Albemarle regularly posts information to Albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, U.S. Securities and Exchange Commission filings and other information regarding the company, its businesses and the markets it serves. 

About KPS Capital Partners

KPS, through its affiliated management entities, is the manager of the KPS Special Situations Funds, a family of investment funds with approximately $19.5 billion of assets under management (as of September 30, 2025). For over three decades, the Partners of KPS have worked exclusively to realize significant capital appreciation by making controlling equity investments in manufacturing and industrial companies across a diverse array of industries, including basic materials, branded consumer, healthcare and luxury products, automotive parts, capital equipment and general manufacturing. KPS creates value for its investors by working constructively with talented management teams to make businesses better, and generates investment returns by structurally improving the strategic position, competitiveness and profitability of its portfolio companies, rather than primarily relying on financial leverage. The KPS Funds’ portfolio companies currently generate aggregate annual revenues of approximately $21.2 billion, operate 202 manufacturing facilities in 21 countries, and have approximately 55,000 employees, directly and through joint ventures

1

Exhibit 99.1

Press Release

worldwide (as of September 30, 2025). The KPS investment strategy and portfolio companies are described in detail at www.kpsfund.com.

Forward-Looking Statements

This press release contains statements concerning our expectations, anticipations and beliefs regarding the future, which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties, often contain words such as “ambition” “anticipate,” “believe,” “estimate,” “expect,” “goals” “guidance,” “intend,” “may,” “outlook,” “scenario,” “should,” “would,” and “will” and similar references to future periods. Forward-looking statements may include statements regarding: plans and expectations regarding use of transaction proceeds, financial flexibility and optionality, future investments and support, value-creation potential, portfolio focus, other underlying assumptions and outlook considerations, and all other information relating to matters that are not historical facts. These and other forward-looking statements are based on management’s current estimates, assumptions and expectations and involve risks and uncertainties that could significantly affect expected results. Actual results could differ materially from those expressed or implied in the forward-looking statements if one or more of the underlying estimates, assumptions or expectations prove to be inaccurate or are unrealized. Factors that could cause Albemarle’s actual results to differ materially from the outlook expressed or implied in any forward-looking statement include: breaches of contract; changes in economic and business conditions; changes in trade policies and tariffs; technological change and development; completion of the audit of our annual financial statements; fluctuations in foreign currencies; changes in laws and government regulation; regulatory actions, proceedings, claims or litigation; cyber-security breaches, terrorist attacks, industrial accidents or natural disasters; geopolitical conflicts and political unrest; trade policies and tariffs; changes in inflation or interest rates; volatility in the debt and equity markets; acquisition and divestiture transactions; timing and success of projects; changes in credit ratings; and the other factors detailed from time to time in the reports Albemarle files with the SEC, including those described under “Risk Factors” in Albemarle’s most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q, which are filed with the SEC and available on the investor section of Albemarle’s website (investors.albemarle.com) and on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date of this press release. Albemarle assumes no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

Investor Relations Contact: +1 (980) 308-6194, invest@albemarle.com

Media Contact: Ryan Dean, +1 (980) 308-6310, media@albemarle.com

2

Exhibit 99.2

Press Release

Albemarle Corporation Announces Cash Tender Offers for Debt Securities and Redemption of 4.650% Senior Notes due 2027

CHARLOTTE, North Carolina, March 2, 2026 – Albemarle Corporation (NYSE: ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced the commencement of cash tender offers for certain series of its debt securities and the full redemption of its 4.650% Senior Notes due 2027.

Cash Tender Offers

The Company has commenced cash tender offers (collectively, the “Offers”) for the maximum principal amount of validly tendered (and not validly withdrawn) (i) 5.650% Senior Notes due 2052 (the “2052 Notes”), (ii) 5.450% Senior Notes due 2044 (the “2044 Notes”), (iii) 3.450% Senior Notes due 2029 (the “2029 Notes”), and (iv) 5.050% Senior Notes due 2032 (the “2032 Notes” and, together with the 2052 Notes, 2044 Notes and 2029 Notes, the “Notes”) set forth below, such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million.

The Offers are being made pursuant to an Offer to Purchase, dated March 2, 2026 (the “Offer to Purchase”), which sets forth a description of the terms of the Offers.

A summary of the Offers to purchase the Notes is outlined below:

Acceptance Priority Level(1)

Title of Security

CUSIP Number

Outstanding Principal Amount

Reference U.S. Treasury Security(2)

Bloomberg Reference Page

Fixed Spread (bps)

Early Tender Premium(3)

1

5.650% Senior Notes due 2052

012653AF8

$450,000,000

4.625% UST due 11/15/2055

FIT 1

+140

$50

2

5.450% Senior Notes due 2044

012725AD9

$350,000,000

4.625% UST due 2/15/2046

FIT 1

+115

$50

3

3.450% Senior Notes due 2029*

01273PAB8 01273PAA0 Q0171YAA8

$171,612,000

3.500% UST due 2/15/2029

FIT 1

+70

$50

4

5.050% Senior Notes due 2032

012653AE1

$600,000,000

3.500% UST due 2/28/2031

FIT 1

+90

$50

(1)The Company is offering to accept the maximum principal amount of validly tendered (and not validly withdrawn) Notes in the Offers for which the aggregate purchase price, not including accrued and unpaid interest, does not exceed $500 million using a “waterfall” methodology under which the Company will accept the Notes in order of their respective Acceptance Priority Levels (as defined below).

(2)The Total Consideration (as defined below) for Notes validly tendered (and not validly withdrawn) prior to or at the Early Tender Time (as defined below) and accepted for purchase is calculated using the applicable fixed spread as described in the Offer to Purchase. The Early Tender Premium of $50 per $1,000 principal amount (the “Early Tender Premium”) is included in the Total Consideration for each series of Notes set forth above and does not constitute an additional or increased payment. Holders of Notes will also receive accrued and unpaid interest on Notes accepted for purchase to, but excluding, the Early Settlement Date or the Final Settlement Date (each as defined below), as applicable.

(3)Per $1,000 principal amount.

*    Denotes a series of Notes issued by Albemarle Wodgina Pty Ltd, an Australian company and a wholly-owned subsidiary of the Company, fully and unconditionally guaranteed on a senior unsecured basis by the Company.

Each Offer is scheduled to expire at 5:00 p.m., New York City time, on March 30, 2026, unless extended or earlier terminated by the Company (such date and time, as the same may be extended or earlier terminated with respect to each Offer, the “Expiration Time”). To receive the Total Consideration, holders of the Notes must validly tender and not validly withdraw Notes at or prior to 5:00 p.m., New York City time, on March 13, 2026, unless such deadline is extended with respect to the applicable Offer (such date and time, as the same may be extended with respect to each Offer, the “Early Tender Time”), to be eligible to receive the Total Consideration. Tenders of Notes may not be validly withdrawn after 5:00 p.m., New York City time, on March 13, 2026 (the “Withdrawal Deadline”), unless extended by the Company with respect to the applicable Offer. After such time, Notes validly tendered may not be validly withdrawn unless such deadline is extended with respect to the applicable Offer, except in certain limited circumstances where additional withdrawal rights are required by law. Payments for Notes validly tendered (and not validly withdrawn) and accepted for purchase at or prior to the Early Tender Time are expected to settle on March 18, 2026 (the “Early Settlement Date”).

The consideration paid in each of the Offers will be determined in the manner described in the Offer to Purchase by reference to a fixed spread over the yield to maturity of the applicable U.S. Treasury Security (the “Reference Treasury Security”) specified in the table above and on the cover page of the Offer to Purchase in the column entitled “Reference U.S. Treasury Security.” Holders who validly tender and do not validly withdraw Notes at or prior to the Early Tender Time that are accepted for purchase will be eligible to receive the “Total Consideration,” which includes an Early Tender Premium of $50 per $1,000 principal amount of Notes accepted for purchase. The Early Tender Premium is included in the Total Consideration for each series of Notes and does not constitute an additional or increased payment. Holders who validly tender Notes after the Early Tender Time but at or prior to the Expiration Time and whose Notes are accepted for purchase will be entitled to receive the Total Consideration minus the Early Tender Premium. In addition, in each case, holders whose Notes are accepted for purchase will receive accrued and unpaid interest on their Notes up to, but excluding, the applicable settlement date, payable on the settlement date.

The Company will accept for purchase for cash the maximum principal amount of validly tendered (and not validly withdrawn) Notes for which the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes does not exceed $500 million (the “Offer Cap”). Subject to the satisfaction or waiver of the conditions of the Offers, Notes validly tendered (and not validly withdrawn) prior to or at the Early Tender Time will be accepted based on the acceptance priority levels noted in the table above (the “Acceptance Priority Levels”). All Notes tendered prior to or at the Early Tender Time will have priority over Notes tendered after the Early Tender Time, regardless of the Acceptance Priority Levels of the Notes tendered after the Early Tender Time. Subject to applicable law, the Company may increase, decrease or waive the Offer Cap, as provided in the Offer to Purchase.

Subject to the satisfaction or waiver of the conditions of the Offers, the “Acceptance Priority Procedures” will operate as follows: (1) at the Early Settlement Date, the Company will accept for purchase all Notes of each series validly tendered at or before the Early Tender Time and not validly withdrawn at or before the Withdrawal Deadline, starting with the 2052 Notes (which have an Acceptance Priority Level of 1), followed by the 2044 Notes (which have an Acceptance Priority Level of 2), followed by the 2029 Notes (which have an Acceptance Priority Level of 3), followed by the 2032 Notes (which have an Acceptance Priority Level of 4), subject to the Offer Cap; and (2) on April 1, 2026 (the “Final Settlement Date”), to the extent the Company has not already accepted Notes with an aggregate purchase price payable in respect of such Notes equal to the Offer Cap, it will accept for purchase validly tendered and not validly withdrawn Notes of each series not previously purchased on the Early Settlement Date starting with the 2052 Notes,

2

followed by the 2044 Notes, followed by the 2029 Notes, followed by the 2032 Notes in accordance with their respective Acceptance Priority Levels, subject to the Offer Cap.

None of the Offers is conditioned on any of the other Offers or upon any minimum principal amount of Notes of any series being tendered. The Company’s obligation to purchase, and to pay for, any Notes validly tendered pursuant to the Offers is subject to and conditioned upon the satisfaction of, or the Company’s waiver of, the conditions described in the Offer to Purchase.

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The Offers are being made solely pursuant to the terms and conditions set forth in the Offer to Purchase.

J.P Morgan Securities LLC, Mizuho Securities USA LLC, Truist Securities, Inc. and U.S. Bancorp Investments, Inc. are serving as Dealer Managers for the Offers (each, a “Dealer Manager” and together, the “Dealer Managers”). Questions regarding the Offers may be directed to J.P Morgan Securities LLC at (866) 834-4666 (toll-free) or (212) 834-3554 (collect), Mizuho Securities USA LLC at (866) 271-7403 (toll-free) or (212) 205-7741 (collect), Truist Securities, Inc. at (833) 594-7730 (toll-free) or U.S. Bancorp Investments, Inc. at (800) 479-3441 (toll-free) or (917) 558-2756 (collect). Requests for the Offer to Purchase or the documents incorporated by reference therein may be directed to Global Bondholder Services Corporation, which is acting as the Tender Agent and Information Agent for the Offers at the following telephone numbers: banks and brokers at (212) 430-3774; all others toll-free at (855) 654-2015.

Redemption

The Company also announced that it will redeem the full outstanding $650,000,000 aggregate principal amount of its 4.650% Senior Notes due 2027 (the “2027 Notes”) (CUSIP No. 012653 AD3) on March 12, 2026 (the “Redemption Date”). On the Redemption Date, the Company will pay to the registered holders of the 2027 Notes a redemption price in an amount equal to the greater of

(1)(a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the Redemption Date (assuming the 2027 Notes matured on the par call date of May 1, 2027) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the treasury rate (determined on the third business day preceding the Redemption Date) plus 30 basis points, less (b) interest accrued to the Redemption Date; and

(2)100% of the principal amount of the 2027 Notes to be redeemed;

plus, in either case, accrued and unpaid interest thereon to the Redemption Date.

A notice of full redemption of the 2027 Notes has been or will be sent to registered holders of the 2027 Notes by U.S. Bank Trust Company, National Association, as trustee under the indenture governing the 2027 Notes. The information concerning the terms and conditions of the redemption is provided in such notice. The information contained in this press release does not constitute a notice of redemption with respect to the 2027 Notes. Investors in the 2027 Notes should contact the bank or broker through which they hold a beneficial interest in the 2027 Notes for information about obtaining the redemption price for the 2027 Notes in which they have a beneficial interest.

About Albemarle

Albemarle Corporation (NYSE: ALB) leads the world in transforming essential resources into critical ingredients for mobility, energy, connectivity and health. We partner to pioneer new ways to move, power,

3

connect and protect with people and planet in mind. A reliable and high-quality global supply of lithium and bromine allows us to deliver advanced solutions for our customers. Learn more about how the people of Albemarle are enabling a more resilient world at Albemarle.com.

Albemarle regularly posts information to Albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, U.S. Securities and Exchange Commission filings and other information regarding the company, its businesses and the markets it serves.

Forward-Looking Statements

This press release contains certain information that are not statements of historical fact or current fact constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties, often contain words such as “anticipate,” “believe,” “estimate,” “expect,” “guidance,” “intend,” “may,” “should,” “would,” “will,” “outlook,” and “scenario.” These and other forward-looking statements are based on management’s current estimates, assumptions and expectations and involve risks and uncertainties that could significantly affect expected results. Actual results could differ materially from those expressed or implied in the forward-looking statements if one or more of the underlying estimates, assumptions or expectations prove to be inaccurate or are unrealized. Additional information concerning factors that could cause actual results to differ materially from those projected is contained in the reports Albemarle files with the SEC, including those described under “Risk Factors” in Albemarle’s most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q, which are filed with the SEC and available on the investor section of Albemarle’s website (investors.albemarle.com) and on the SEC’s website at www.sec.gov.

Albemarle assumes no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

Investor Relations Contact: +1 (980) 308-6194, invest@albemarle.com

Media Contact: Ryan Dean, +1 (980) 308-6310, media@albemarle.com

4

FAQ

What business did Albemarle (ALB) sell in the Ketjen transaction?

Albemarle sold its 51% ownership interest in Ketjen Corporation, whose business focuses on developing, manufacturing and marketing catalysts and related products globally. Albemarle retains a 49% minority stake in Ketjen and continues to own 100% of the Performance Catalyst Solutions business.

How much cash does Albemarle (ALB) expect from the Ketjen and Eurecat sales?

Albemarle expects approximately $547 million in cash from the Ketjen sale, including $22 million of cash held by Ketjen. Together with the sale of its 50% Eurecat joint-venture interest, combined pre-tax proceeds from the two transactions total about $670 million for the company.

How will Albemarle (ALB) use the proceeds from the Ketjen and Eurecat transactions?

Albemarle expects to use the transaction proceeds primarily for debt reduction and other general corporate purposes. Actions include cash tender offers for up to $500 million of certain senior notes and the full redemption of $650,000,000 of 4.650% Senior Notes due 2027, as announced.

What debt securities are included in Albemarle’s (ALB) $500 million tender offers?

The cash tender offers cover four series: 5.650% Senior Notes due 2052, 5.450% Senior Notes due 2044, 3.450% Senior Notes due 2029 issued by Albemarle Wodgina Pty Ltd, and 5.050% Senior Notes due 2032, with a total purchase price cap of $500 million excluding accrued interest.

What is Albemarle (ALB) doing with its 4.650% Senior Notes due 2027?

Albemarle will redeem the full outstanding $650,000,000 principal amount of its 4.650% Senior Notes due 2027 on March 12, 2026. Holders will receive a redemption price calculated under the indenture plus accrued and unpaid interest to the redemption date, as detailed in the redemption notice.

Does Albemarle (ALB) still have an interest in Ketjen after the sale?

Yes. After selling a controlling stake to an affiliate of KPS Capital Partners, Albemarle retains a 49% minority ownership interest in Ketjen. KPS holds a majority of Ketjen’s Board of Directors and operational control, while Albemarle remains an investor alongside its separate catalyst solutions operations.

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 EX-99.1 14.5 KB
• EX-99.2 EX-99.2 38.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2.1 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT 6.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 26.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 17.1 KB